Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06574880 · ClinicalTrials.gov registry record · Phase 1
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
A Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer, sponsored by Angela Y. Jia, MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06574880 is a Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer that is actively recruiting participants, run by Angela Y. Jia, MD PhD. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06574880, a Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer, is actively recruiting participants, sponsored by Angela Y. Jia, MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.
Conditions Studied
Interventions
- DRUG Lu-PSMA-617
- RADIATION 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06574880
The ClinicalTrials.gov registry entry for NCT06574880 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angela Y. Jia, MD PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Neoplasm of Prostate appearing as the primary indexed condition, and to 2 interventions - of which Lu-PSMA-617 is the first listed.
NCT06574880 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06574880 about?
NCT06574880 is a clinical study titled "STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer". The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants w...
What is the current status of trial NCT06574880?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-05-13. Estimated completion is 2027-03-01.
What conditions does trial NCT06574880 study?
This clinical trial studies the following conditions: Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer.
What interventions are being tested in trial NCT06574880?
The interventions under investigation include: Lu-PSMA-617 (DRUG), 5-fraction Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT06574880?
This trial is sponsored by Angela Y. Jia, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06574880 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm of Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.